Ulcerative Colitis

A chronic disease with significant unmet need
Requiring treatment of the underlying cause, not just symptoms

Mild-to-moderate ulcerative colitis

A chronic, autoimmune, inflammatory bowel disease

  • Affecting 5 million people, with increasing incidence year on year.
  • A life-long disease with a significant impact on quality of life with risk of life-threatening conditions.
  • Symptoms include debilitating diarrhoea, abdominal pain, rectal bleeding, fatigue.
  • Current treatment options are limited to management of symptoms by suppressing inflammation, rather than targeting the underlying issue.
  • Repeated active and remission periods.
  • 5-10 year cumulative risk of colectomy 10-15%

    • microbiome therapeutics Ulcerative colitis Crohn's disease treatment IBD

    MH002 – a novel treatment strategy in IBD

    Immune modulation and restoration

    microbiome therapeutics Ulcerative colitis Crohn's disease treatment IBD

    The most advanced rationally-designed consortium therapy for Ulcerative Colitis

    MH002 – our lead clinical program

    A multi-center, double-blind, randomized, placebo-controlled trial has been completed in 45 UC patients at multiple clinical sites in Belgium, Poland and Czech Republic.

    The trial aimed to evaluate safety (primary endpoint), initial efficacy and mechanistic effects of MH002 over eight weeks, with a further eight-week extension period.

    More information on the Phase 2a trial design

    MH002: Encouraging topline Phase 2a data

    microbiome therapeutics Ulcerative colitis Crohn's disease treatment IBD

    For more information, see our press release